Members |
targetComponentId |
Miscellaneous operations NOS |
Intentional, structural alteration of the human body by mechanical, thermal, light-based, electromagnetic, or chemical means, and/or by the incision or destruction of tissues using instruments to cut, burn, vaporize, freeze, suture, probe, or manipulate by closed reductions. |
Miscellaneous operations NOS |
Intentional, structural alteration of the human body by mechanical, thermal, light-based, electromagnetic, or chemical means, and/or by the incision or destruction of tissues using instruments to cut, burn, vaporize, freeze, suture, probe, or manipulate by closed reductions. |
Miscellaneous positions |
Body position finding |
Miscellaneous postnatal data |
Puerperium observable |
Miscellaneous postnatal data NOS |
Puerperium observable |
Miscellaneous postnatal data NOS |
Puerperium observable |
Miscellaneous sample for organism |
Sample sent for examination |
Miscellaneous samples NOS |
Sample examination - general |
Miscellaneous topical preparations allergy |
A pathological immune process generally directed towards a foreign antigen, which results in tissue injury, which is usually transient. It is the realization of the allergic disposition. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. |
Mitomycin 40mg injection solution vial |
Product containing precisely mitomycin 40 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Mitomycin 40mg/vial injection |
Product containing precisely mitomycin 40 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Mitomycin 5mg injection solution vial |
Mitomycin 5 mg powder for solution for injection vial |
Mitomycin 5mg/vial injection |
Mitomycin 5 mg powder for solution for injection vial |
Mitral valve appearance |
Mitral valve appearance (observable entity) |
Mitral valve orifice appearance |
Mitral valve orifice appearance (observable entity) |
Mitral valvuloplasty NEC |
Mitral valvuloplasty (procedure) |
Mixed cell type lymphosarcoma of extranodal AND/OR solid organ site |
Non-Hodgkin's lymphoma (clinical) |
Mixed cell type lymphosarcoma of lymph nodes of axilla AND/OR upper limb (disorder) |
Malignant lymphoma of lymph nodes of upper limb (disorder) |
Mixed cell type lymphosarcoma of lymph nodes of inguinal region and lower limb |
Malignant lymphoma of lymph nodes of lower limb (disorder) |
Mixed cell type lymphosarcoma of lymph nodes of multiple sites |
Malignant lymphoma of lymph nodes |
Mixed cell type lymphosarcoma of spleen |
Non-Hodgkin's lymphoma (clinical) |
Mixed feto-pelvic disproportion with antenatal problem |
Mixed feto-pelvic disproportion |
Mixed germ cell-sex cord-stromal tumor, no International Classification of Diseases for Oncology subtype |
Mixed germ cell-sex cord-stromal tumor (morphologic abnormality) |
Mixed molds radioallergosorbent test |
Fungal mix specific IgE antibody measurement |
Mixed moulds RAST test |
Fungal mix specific IgE antibody measurement |
Mixed moulds RAST test |
Fungal mix specific IgE antibody measurement |
Mixed nut (fx1) radioallergosorbent test |
Peanut+hazelnut+Brazil nut+almond+coconut specific IgE antibody measurement |
Mixed nut (fx22) radioallergosorbent test |
Pecan nut+cashew nut+ pistachio+walnut specific immunoglobulin E antibody measurement (procedure) |
Mixed renal tubular acidosis |
Renal tubular acidosis |
Mixtard insulin adverse reaction |
Insulin adverse reaction |
Mixtard insulin allergy |
Allergy to insulin |
Mobile X-ray in vehicle |
Portable plain X-ray (procedure) |
Mobile X-ray in vehicle |
Portable plain X-ray (procedure) |
Mobile X-ray in ward |
Portable plain X-ray (procedure) |
Mobile X-ray in ward |
Portable plain X-ray (procedure) |
Mobility NOS |
Finding related to ability to mobilize |
Mobility NOS |
Finding related to ability to mobilize |
Mobility allowance medical examination NOS |
Mobility allowance medical |
Mobility allowance medical examination NOS |
Mobility allowance medical |
Moderate asthma |
Moderate asthma |
Moderate midline deviation of maxillary tooth position to left |
Moderate midline deviation of maxillary dental arch to left (finding) |
Moderate midline deviation of maxillary tooth position to right |
Moderate midline deviation of maxillary dental arch to right |
Modified release isosorbide dinitrate allergy |
Allergy to isosorbide (finding) |
Modified release isosorbide mononitrate allergy |
Allergy to isosorbide (finding) |
Mohs' chemosurgery, fresh tissue technique |
Mohs' chemosurgery |
Mold mix RAST test |
Fungal mix specific IgE antibody measurement |
Molgramostim 300micrograms powder for injection solution vial |
Product containing only molgramostim in parenteral dose form (medicinal product form) |
Molindone hydrochloride 20mg/mL |
Product containing only molindone (medicinal product) |
Molluscum contagiosum subgroup virus |
Genus Molluscipoxvirus (organism) |
Molluscum contagiosum with eyelid involvement |
Infection of skin of eyelid caused by Molluscum contagiosum (disorder) |
Molluscum contagiosum with eyelid involvement |
Infection of skin of eyelid caused by Molluscum contagiosum (disorder) |
Mollusk |
Phylum Mollusca (organism) |
Mollusk - dietary |
Marine mollusk (substance) |
Mometasone furoate 200micrograms cap activated dry powder inhaler |
Product containing only mometasone in pulmonary dose form (medicinal product form) |
Monarticular juvenile rheumatoid arthritis |
A rare inflammatory rheumatic disease characterised by juvenile onset arthritis that affects fewer than 5 joints during the first 6 months after disease onset. |
Monitoring drug withdrawal |
Monitoring substance withdrawal |
Monitoring of cardiac output by other technique |
Monitoring of cardiac output/cardiac index |
Monitoring of patient NOS |
Monitoring of patient |
Monitoring of patient NOS |
Monitoring of patient |
Monitoring of pressure in organ NOC |
Physiological monitoring regime (regime/therapy) |
Monitoring patient temperature by nurse |
Monitoring of patient temperature (regime/therapy) |
Monoarticular juvenile rheumatoid arthritis |
A rare inflammatory rheumatic disease characterised by juvenile onset arthritis that affects fewer than 5 joints during the first 6 months after disease onset. |
Monochloroacetate |
Chloroacetic acid |
Monoclonal gene rearrangement |
T cell gene rearrangement analysis (procedure) |
Monocyte count NOS |
Monocyte count |
Monocyte count NOS |
Monocyte count |
Monocytic leukemia in remission |
Myeloid leukemia in remission |
Monocytoid B-cell lymphoma |
Marginal zone B-cell lymphoma |
Monooxygenase |
Monooxygenase |
Monosporium apiospermum |
Scedosporium boydii |
Monster NOS |
Congenital malformation |
Monster with cranial anomalies |
Congenital anomaly of skull |
Monstrocellular sarcoma |
Giant cell glioblastoma |
Montelukast sodium 4mg oral granules |
Product containing precisely montelukast (as montelukast sodium) 4 milligram/1 sachet conventional release oral granules (clinical drug) |
Monterey fluency program |
Monterey Fluency Program (regime/therapy) |
Mood disorder caused by ingestible alcohol |
Mood disorder caused by ethanol (disorder) |
Mood disorder with depressive symptoms caused by alcohol |
Mood disorder with depressive symptoms caused by ethanol |
Mood disorder with manic symptoms caused by alcohol |
Mood disorder with manic symptoms caused by ethanol (disorder) |
Mood disorder with mixed manic and depressive symptoms caused by alcohol |
Mood disorder with mixed manic and depressive symptoms caused by ethanol |
Moraxella (Moraxella) phenylpyruvica |
Psychrobacter phenylpyruvicus |
Moraxella anatipestifer |
Riemerella anatipestifer |
More supplement & complete foods [1] |
Nutritional supplement (substance) |
More supplement & complete foods [3] |
Nutritional supplement (substance) |
Morphinan cough suppressant |
Morphinan opioid |
Morphinan cough suppressant adverse reaction |
Morphinan opioid adverse reaction |
Morphinan cough suppressant allergy |
Allergy to morphinan opioid |
Morphine - non-pharmaceutical |
Morphine (substance) |
Morphine hydrochloride 10mg/mL oral solution |
Product containing precisely morphine sulfate 10 milligram/1 milliliter conventional release oral solution (clinical drug) |
Morphine sulfate 100mg + naltrexone hydrochloride 4mg m/r capsule |
Product containing only morphine and naltrexone in oral dose form (medicinal product form) |
Morphine sulfate 100mg + naltrexone hydrochloride 4mg prolonged-release oral capsule |
Product containing only morphine and naltrexone in oral dose form (medicinal product form) |
Morphine sulfate 100mg rectal tampon |
Morphine sulfate 100 mg rectal suppository |
Morphine sulfate 100mg/sachet granules for suspension |
Product containing precisely morphine sulfate 5 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Morphine sulfate 10mg/mL extended release liposome injection |
Morphine sulfate liposome 10 mg/mL solution for injection |
Morphine sulfate 200mg/sachet granules for suspension |
Product containing precisely morphine sulfate 6.67 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Morphine sulfate 20mg + naltrexone hydrochloride 800microgram m/r capsule |
Product containing only morphine and naltrexone in oral dose form (medicinal product form) |
Morphine sulfate 20mg + naltrexone hydrochloride 800microgram prolonged-release oral capsule |
Product containing only morphine and naltrexone in oral dose form (medicinal product form) |
Morphine sulfate 20mg/sachet granules for suspension |
Product containing precisely morphine sulfate 2 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Morphine sulfate 30mg + naltrexone hydrochloride 1.2mg m/r capsule |
Product containing only morphine and naltrexone in oral dose form (medicinal product form) |
Morphine sulfate 30mg + naltrexone hydrochloride 1.2mg prolonged-release oral capsule |
Product containing only morphine and naltrexone in oral dose form (medicinal product form) |
Morphine sulfate 30mg/5mL oral unit dose vial |
Product containing precisely morphine sulfate 6 milligram/1 milliliter conventional release oral solution (clinical drug) |
Morphine sulfate 30mg/sachet granules for suspension |
Morphine sulfate 3 mg/mL oral suspension |